Clinical Trial Update: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Rina-S plus standard of care versus standard of care for maintenance therapy in recurrent platinum-sensitive ovarian cancer after seco…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Platinum-sensitive Ovarian Cancer

Drugs mentioned

• Rina-S

Snippet

Sponsor: Genmab | Conditions: Ovarian Cancer, Platinum-sensitive Ovarian Cancer | Phase 3 | Status: RECRUITING